Biocryst Pharmaceuticals Stock Buy Hold or Sell Recommendation
| BCRX Stock | USD 7.50 0.01 0.13% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding BioCryst Pharmaceuticals is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell BioCryst Pharmaceuticals given historical horizon and risk tolerance towards BioCryst Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for BioCryst Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out BioCryst Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as BioCryst and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
BioCryst |
Execute BioCryst Pharmaceuticals Buy or Sell Advice
The BioCryst recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BioCryst Pharmaceuticals. Macroaxis does not own or have any residual interests in BioCryst Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioCryst Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
BioCryst Pharmaceuticals Trading Alerts and Improvement Suggestions
| BioCryst Pharmaceuticals generated a negative expected return over the last 90 days | |
| BioCryst Pharmaceuticals has high historical volatility and very poor performance | |
| BioCryst Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 331.41 M. Net Loss for the year was (226.54 M) with profit before overhead, payroll, taxes, and interest of 10.94 M. | |
| BioCryst Pharmaceuticals currently holds about 417.48 M in cash with (95.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.24. | |
| BioCryst Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: BioCryst Pharmaceuticals, Inc. Is Expected To Breakeven In The Near Future |
BioCryst Pharmaceuticals Returns Distribution Density
The distribution of BioCryst Pharmaceuticals' historical returns is an attempt to chart the uncertainty of BioCryst Pharmaceuticals' future price movements. The chart of the probability distribution of BioCryst Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use BioCryst Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BioCryst Pharmaceuticals returns is essential to provide solid investment advice for BioCryst Pharmaceuticals.
| Mean Return | -0.09 | Value At Risk | -4.52 | Potential Upside | 5.24 | Standard Deviation | 3.20 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BioCryst Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BioCryst Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as BioCryst Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading BioCryst Pharmaceuticals back and forth among themselves.
| Shares | Rock Springs Capital Management Lp | 2024-06-30 | 3.6 M | Fisher Asset Management, Llc | 2024-09-30 | 3.3 M | Gw&k Investment Management, Llc | 2024-09-30 | 3.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3.2 M | Goldman Sachs Group Inc | 2024-06-30 | 2.5 M | Rice Hall James & Associates, Llc | 2024-09-30 | 2.2 M | Fmr Inc | 2024-09-30 | 2 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.9 M | Two Sigma Advisers, Llc | 2024-06-30 | 1.9 M | Vanguard Group Inc | 2024-09-30 | 20.3 M | Blackrock Inc | 2024-06-30 | 20 M |
BioCryst Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 87.4M | 158.6M | 233.4M | (201.5M) | (193.8M) | (184.1M) | |
| Free Cash Flow | (89.9M) | (137.7M) | (144.5M) | (163.2M) | (97.3M) | (92.4M) | |
| Depreciation | 724K | 748K | 777K | 1.4M | 1.7M | 970.6K | |
| Other Non Cash Items | 1.3M | 2.4M | 54.2M | 98.1M | 106.5M | 111.9M | |
| Capital Expenditures | 343K | 514K | 2.4M | 1.4M | 2.2M | 2.1M | |
| Net Income | (108.9M) | (182.8M) | (184.1M) | (247.1M) | (226.5M) | (215.2M) | |
| End Period Cash Flow | 115.7M | 274.3M | 507.7M | 306.2M | 112.4M | 66.1M | |
| Change To Inventory | 1.6M | (7.0M) | (8.8M) | (12.4M) | (1.5M) | (1.5M) | |
| Investments | 78.3M | (6.3M) | 18.2M | (128.2M) | (25.8M) | (24.5M) | |
| Change Receivables | 1.8M | (17.9M) | 13.9M | (20.8M) | (18.7M) | (17.8M) | |
| Change To Netincome | 18.1M | 15.4M | 33.0M | 141.8M | 163.1M | 171.3M | |
| Net Borrowings | 19.5M | 67.4M | 293.9M | 73.1M | 84.0M | 64.6M |
BioCryst Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioCryst Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioCryst Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioCryst stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.36 | |
β | Beta against Dow Jones | 2.13 | |
σ | Overall volatility | 3.21 | |
Ir | Information ratio | -0.07 |
BioCryst Pharmaceuticals Volatility Alert
BioCryst Pharmaceuticals exhibits very low volatility with skewness of -0.57 and kurtosis of 3.58. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure BioCryst Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact BioCryst Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.BioCryst Pharmaceuticals Fundamentals Vs Peers
Comparing BioCryst Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioCryst Pharmaceuticals' direct or indirect competition across all of the common fundamentals between BioCryst Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioCryst Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BioCryst Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioCryst Pharmaceuticals to competition |
Note: Acquisition by Jon Stonehouse of 10000 shares of BioCryst Pharmaceuticals subject to Rule 16b-3 [view details]
BioCryst Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioCryst . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About BioCryst Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell BioCryst Pharmaceuticals? Buying financial instruments such as BioCryst Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having BioCryst Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Care ETFs Thematic Idea Now
Health Care ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Health Care ETFs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Care ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.